Revelation Biosciences, Inc. (REVB) NASDAQ
1.16
+0.01000005(+0.87%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.16
+0.01000005(+0.87%)
Currency In USD
Address
4660 La Jolla Village Drive
San Diego, CA 92122
United States of America (the)
Phone
650 800 3717
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
November 17, 2020
| Name | Title | Pay | Year Born |
| James Rolke | Chairman & Chief Executive Officer | 813,226 | 1969 |
| Chester Stanley Zygmont | Chief Financial Officer & Corporate Secretary | 564,006 | 1980 |
| Carol Odle | Senior Director of Clinical Projects | 0 | N/A |
| Sandra Vedrick | Vice President of Human Resources & Investor Relations | 0 | N/A |
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.